Eric Langer | 10/23/2014
Biopharmaceutical companies that get stuck with legacy technologies, including older stainless steel equipment, and older processes, end up watching as competitors transition to more efficient, cost-effective platforms. But this isn’t just a cost-of-production issue; it goes to more strategic factors like being able to even participate in the emerging biosimilars markets, as well as being able to participate in global emerging economies.
Our 11thAnnual Report of Biopharmace...
To continue reading this story Click Here
RECOMMENDED
Digital Transformation in Pharma: Navigating CMO Partnerships and Supply Chain Resilience
2025-01-22
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More